Mechanism, Phase 2 trial data, titration protocol, reconstitution, and COA-verified vendor pricing — everything in one place.
Research purposes only. Cagrilintide is a research compound. This content is for educational reference only and does not constitute medical advice. Not for human consumption.
Cagrilintide is a fatty acid-conjugated long-acting amylin analog developed by Novo Nordisk. It activates amylin receptors (CALCR/RAMP1/RAMP3) — a completely separate pathway from GLP-1, GIP, or glucagon receptors. This mechanistic independence makes it additive rather than redundant when combined with GLP-1 agonists.
Its 7-day half-life, achieved through albumin-binding fatty acid conjugation, enables once-weekly dosing in research protocols. The compound has completed Phase 2 trials as a standalone and is currently in Phase 3 evaluation as part of the CagriSema combination with semaglutide 2.4mg.
Natural amylin is co-secreted with insulin from pancreatic beta cells after meals. It signals satiety, slows gastric emptying, and suppresses glucagon — all via calcitonin receptor complexes rather than the incretin receptors that GLP-1 drugs target.
Cagrilintide replicates and extends this signaling with engineered stability. The mechanism breaks down into four distinct effects:
Why this matters for CagriSema: Because GLP-1 and amylin operate through separate receptor systems, combining semaglutide with cagrilintide doesn't produce receptor saturation or competition — it produces complementary signaling. That's the mechanistic basis for the observed additive weight loss in combination trials.
The Phase 2 standalone trial enrolled 706 adults with obesity (BMI ≥30) and ran 26 weeks with dose titration. The trial used a placebo-controlled, parallel-group design with five dose cohorts.
| Dose Group | Body Weight Change | Notes |
|---|---|---|
| Placebo | -3.0% | Background effect |
| 0.3mg weekly | -6.0% | Lowest active dose |
| 0.6mg weekly | -8.1% | |
| 1.2mg weekly | -10.8% | |
| 2.4mg weekly | -15.6% | Highest dose studied; primary endpoint |
Clear dose-response relationship across all cohorts. GI side effects (nausea, vomiting) were dose-dependent and most common during titration — consistent with the amylin receptor mechanism. No significant cardiovascular safety signals at Phase 2 durations.
A 32-week Phase 2 study evaluated cagrilintide 2.4mg + semaglutide 2.4mg (CagriSema) versus each component alone. The combination arm showed weight loss numerically superior to both monotherapy arms, consistent with the mechanistic hypothesis of additive receptor engagement.
The REDEFINE Phase 3 program is testing CagriSema in obesity (REDEFINE 1), type 2 diabetes (REDEFINE 2), and cardiovascular risk populations. These readouts will determine the regulatory trajectory.
Based on Phase 2 trial design. All protocols are for research purposes only.
| Weeks | Dose | Frequency | Notes |
|---|---|---|---|
| 1–4 | 0.25mg | Once weekly | Starting dose; minimal GI effects expected |
| 5–8 | 0.5mg | Once weekly | Advance only if previous dose well tolerated |
| 9–12 | 1.0mg | Once weekly | |
| 13–16 | 1.7mg | Once weekly | |
| 17+ | 2.4mg | Once weekly | Maintenance dose used in Phase 2 high-dose arm |
Titration rule: Hold at current dose for an additional 4 weeks if nausea or GI effects are present. Do not advance during active symptoms.
Cagrilintide is supplied as a lyophilized powder. Reconstitute with bacteriostatic water before use.
For a full walkthrough of reconstitution principles and syringe calculations, see the Reconstitution Guide →
Pricing and availability from vetted domestic vendors. All vendors below provide Certificates of Analysis.
Current pricing with promo codes and COA links — updated regularly from vendor feeds.
View Cagrilintide Pricing → Dosage Calculator